Published in Neurology on April 04, 2014
Fibroblast growth factor 23 and risk of incident stroke in community-living adults. Stroke (2015) 2.06
Plasma fibroblast growth factor 23 and risk of cardiovascular disease: results from the EPIC-Germany case-cohort study. Eur J Epidemiol (2014) 0.84
Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study. PLoS One (2015) 0.83
Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy. Front Endocrinol (Lausanne) (2015) 0.83
Evidence to Maintain the Systolic Blood Pressure Treatment Threshold at 140 mm Hg for Stroke Prevention: The Northern Manhattan Study. Hypertension (2016) 0.82
Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study. J Clin Endocrinol Metab (2016) 0.82
Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area: The Northern Manhattan Study. Arterioscler Thromb Vasc Biol (2015) 0.78
Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate. J Bone Miner Metab (2015) 0.76
Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study. Stroke (2016) 0.76
Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease. Curr Opin Nephrol Hypertens (2015) 0.75
Fibroblast Growth Factor-23 (FGF-23) Levels Differ Across Populations by Degree of Industrialization. J Clin Endocrinol Metab (2016) 0.75
Serum phosphorus levels and risk of incident dementia. PLoS One (2017) 0.75
Fibroblast growth factor-23 is independently associated with cardiac mass in African-American adolescent males. J Am Soc Hypertens (2017) 0.75
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med (2012) 14.99
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
The behavioral risk factor surveys: II. Design, methods, and estimates from combined state data. Am J Prev Med (1988) 7.67
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol (1998) 5.54
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Race-ethnic disparities in the impact of stroke risk factors: the northern Manhattan stroke study. Stroke (2001) 4.07
Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation (2012) 3.07
Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int (2010) 3.04
FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int (2011) 2.71
Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis (2009) 2.70
Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int (2012) 2.61
Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol (2012) 2.22
Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res (2005) 2.15
Race and ethnic standards for Federal statistics and administrative reporting. Stat Report (1977) 2.02
Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: findings from the Northern Manhattan Study (NOMAS). Diabetes Care (2008) 1.69
25-hydroxyvitamin D and symptomatic ischemic stroke: an original study and meta-analysis. Ann Neurol (2012) 1.58
Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) (1999) 1.29
Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. J Clin Endocrinol Metab (2012) 1.21
Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol (2013) 1.10
Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. Clin J Am Soc Nephrol (2012) 1.02
Longitudinal analysis of vascular function and biomarkers of metabolic bone disorders before and after renal transplantation. Am J Nephrol (2013) 0.96
Serum vitamin D and parathyroid hormone in relation to cardiac structure and function: the ICELAND-MI substudy of AGES-Reykjavik. J Clin Endocrinol Metab (2013) 0.94
Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study. BMC Nephrol (2013) 0.92
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43
Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet (2014) 10.06
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 6.41
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol (2005) 5.76
Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2007) 5.26
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation (2002) 4.69
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation (2005) 4.08
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke (2008) 4.06
Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA (2012) 3.67
An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2013) 3.60
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA (2004) 3.51
Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med (2012) 3.50
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int (2009) 3.41
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation (2005) 3.25
Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke (2008) 3.21
Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. Circulation (2012) 3.14
Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA (2012) 3.10
Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol (2008) 3.00
Effects of phosphate binders in moderate CKD. J Am Soc Nephrol (2012) 2.92
The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. Circulation (2011) 2.89
Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol (2012) 2.83
National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol (2006) 2.82
Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes (2009) 2.70
Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association. Stroke (2013) 2.66
Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrol Dial Transplant (2011) 2.60
Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale: analysis of putative high-risk features from the risk of paradoxical embolism database. Circ Cardiovasc Imaging (2013) 2.56
Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke (2007) 2.55
Moderate alcohol consumption reduces risk of ischemic stroke: the Northern Manhattan Study. Stroke (2005) 2.51
Ideal cardiovascular health predicts lower risks of myocardial infarction, stroke, and vascular death across whites, blacks, and hispanics: the northern Manhattan study. Circulation (2012) 2.48
Relationship between periodontal disease, tooth loss, and carotid artery plaque: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Stroke (2003) 2.45
2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol (2012) 2.44
Aortic arch plaques and risk of recurrent stroke and death. Circulation (2009) 2.40
Comparison of 30-day mortality models for profiling hospital performance in acute ischemic stroke with vs without adjustment for stroke severity. JAMA (2012) 2.38
Stroke in the young in the northern Manhattan stroke study. Stroke (2002) 2.37
Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes (2010) 2.36
Patent foramen ovale and stroke. Circulation (2005) 2.34
Traditional risk factors are not major contributors to the variance in carotid intima-media thickness. Stroke (2013) 2.34
Relation of plasma glucose and endothelial function in a population-based multiethnic sample of subjects without diabetes mellitus. Am J Cardiol (2005) 2.34
Long-term functional recovery after first ischemic stroke: the Northern Manhattan Study. Stroke (2009) 2.33
Risk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study. Stroke (2007) 2.30
An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology (2013) 2.26
Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans. Am J Psychiatry (2014) 2.26
Remote ischemic limb preconditioning after subarachnoid hemorrhage: a phase Ib study of safety and feasibility. Stroke (2011) 2.26
Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant (2010) 2.23
Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J (2006) 2.22
Advancing the study of stroke in women: summary and recommendations for future research from an NINDS-Sponsored Multidisciplinary Working Group. Stroke (2006) 2.17
Left ventricular mass and geometry and the risk of ischemic stroke. Stroke (2003) 2.15
Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol (2007) 2.15
Association between incident cancer and subsequent stroke. Ann Neurol (2015) 2.13
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab (2009) 2.12
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis (2013) 2.09
Infectious burden and risk of stroke: the northern Manhattan study. Arch Neurol (2009) 2.08